Q1 EPS Estimate for Dynavax Technologies Reduced by Analyst

Dynavax Technologies Co. (NASDAQ:DVAX) – Research analysts at William Blair lowered their Q1 2025 EPS estimates for shares of Dynavax Technologies in a report released on Friday, February 21st. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $0.03 for the quarter, down from their previous estimate of $0.04. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.32 per share. William Blair also issued estimates for Dynavax Technologies’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.28 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.18 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.11 EPS and FY2026 earnings at $0.61 EPS.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.05. The business had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%.

DVAX has been the topic of a number of other reports. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday. The Goldman Sachs Group downgraded shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. Finally, HC Wainwright restated a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a report on Friday.

Dynavax Technologies Stock Performance

Shares of DVAX stock opened at $13.42 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a market capitalization of $1.76 billion, a P/E ratio of 74.56 and a beta of 1.32. The company’s 50 day moving average price is $12.83 and its two-hundred day moving average price is $12.06. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $14.05.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. increased its stake in shares of Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 1,169 shares during the period. Smartleaf Asset Management LLC increased its position in Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares during the period. US Bancorp DE increased its position in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Dynavax Technologies during the 4th quarter valued at approximately $35,000. Finally, Capital Performance Advisors LLP acquired a new stake in Dynavax Technologies during the 3rd quarter valued at approximately $45,000. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.